Navigation Links
STELARA(TM) Shows Greater Efficacy Than Etanercept for Treatment of Moderate to Severe Plaque Psoriasis: Phase 3 Comparator Study Published in The New England Journal of Medicine
Date:1/14/2010

HORSHAM, Pa., Jan. 14 /PRNewswire/ -- Findings from an international, Phase 3 clinical study comparing the efficacy and safety of STELARA™ (ustekinumab) with etanercept (Enbrel®) in the treatment of moderate to severe plaque psoriasis appear today in The New England Journal of Medicine.  The results showed a significantly higher clinical response with both doses of STELARA than with etanercept over a 12-week period.  The first-of-its-kind head-to-head study comparing two biologic agents for plaque psoriasis also shows the efficacy of STELARA among patients in the study who failed to respond to etanercept.

Psoriasis is an inflammatory disorder characterized by raised, inflamed, red lesions, or plaques, which can cause physical pain.  It is estimated that approximately 7.5 million Americans and nearly 3 percent of the world's population are living with psoriasis, which can present in various forms, ranging from mild to severe and disabling. 

"This study provides important comparative efficacy information about the treatment of moderate to severe plaque psoriasis with two biologic agents," said professor Christopher Griffiths, MD, FRCP, University of Manchester, Manchester, UK, and lead trial investigator.  "We observed a substantial proportion of patients achieving high levels of skin clearance with ustekinumab, both through the study's primary endpoint at week 12 and following crossover from etanercept, including in those patients who showed a lack of response to etanercept during the study."

In the comparator study, 68 and 74 percent of patients receiving subcutaneous injections of STELARA (45 mg or 90 mg) at weeks 0 and 4 achieved at least a 75 percent reduction in psoriasis as measured by the Psoriasis
'/>"/>

SOURCE Centocor Ortho Biotech Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
2. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
3. Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
4. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
5. Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
6. Cleveland Clinic Study Shows the Diabetes Drug Pioglitazone Reduces Risk of Death, Heart Attack and Stroke, but Increases Risk of Heart Failure
7. New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
8. Feeling Anxious or Distracted? New Research Shows a Cup of Tea Could Help
9. New Study Shows Once-Monthly Boniva(R) is as Clinically Effective as Once-Weekly Fosamax(R) at Increasing Bone Mineral Density in Postmenopausal Women With Osteoporosis
10. Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia
11. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Jan. 23, 2015 For the pharmaceutical industry, marketplace success ... payers. Likewise, the importance of the managed markets function - ... to grow as payer formularies and provider networks play an ... At the same time, managed markets leaders must continually identify ...
(Date:1/23/2015)... ANGELES , Jan. 23, 2015 A lot of ... best methods for treating  certain illnesses, injuries, or conditions. As ... replace previous treatment methods with ones that they consider to ... hernias, there is not one textbook method of treatment that ...
(Date:1/23/2015)... , Jan. 23, 2015  A new analysis of ... D 2015 enrollment data shows that 81 percent of ... access and extra discounts at certain pharmacies. The findings ... "Preferred pharmacy plans are now the foundation of Medicare ...
Breaking Medicine Technology:As Payer Influence Rises, Pharmaceutical Companies work to Optimize the Managed Markets Function 2No One-Size-Fits-All Remedy for Hernia Correction 2New Analysis: 81 Percent of Medicare Part D Seniors Choose "Preferred Pharmacy" Plans in 2015 2
... YORK, Nov. 5 - Top experts from the,Alzheimer,s ... widespread,utilization of memory screenings, especially in light of ... are not recognized,often enough and that early diagnosis ... Eric J. Hall, AFA,s chief executive officer, ...
... Nov. 5 Synvista Therapeutics,Inc. (Amex: SYI ... as the ICARE,study, being presented today at the ... Florida. The study demonstrated that,supplementing Vitamin E therapy ... Haptoglobin 2-2 (Hp2-2) phenotype met its pre-specified, primary,endpoint ...
Cached Medicine Technology:Experts Call for Widespread Use of Memory Screenings and Emphasize Value of Early Detection of Dementia 2Experts Call for Widespread Use of Memory Screenings and Emphasize Value of Early Detection of Dementia 3Experts Call for Widespread Use of Memory Screenings and Emphasize Value of Early Detection of Dementia 4Synvista Therapeutics Highlights New Data Demonstrating the Clinical Benefit of Vitamin E Therapy in Patients Identified on the Basis of Haptoglobin Phenotype Testing 2Synvista Therapeutics Highlights New Data Demonstrating the Clinical Benefit of Vitamin E Therapy in Patients Identified on the Basis of Haptoglobin Phenotype Testing 3Synvista Therapeutics Highlights New Data Demonstrating the Clinical Benefit of Vitamin E Therapy in Patients Identified on the Basis of Haptoglobin Phenotype Testing 4
(Date:1/22/2015)... (PRWEB) January 22, 2015 For over 20 years, ... Oceanside and Vista area has treated just about every ... personal injury circumstances. And for those same twenty-plus years, the ... of all those injuries with the best possible doctor. ...
(Date:1/22/2015)... 22, 2015 Yesterday, Senator Holly ... and Kristin Olsen (R-Modesto) were honored by the ... advancing biotechnology, biomedical science, medical device and pharmaceutical ... received the “2014 Life Sciences Champion” award from ...
(Date:1/22/2015)... Payday lending practices in four southern ... financial distress to the states that permit them, according ... Center on Race and Wealth. , While they generate ... loans at the same time substantially depress economic activity, ...
(Date:1/22/2015)... Compare-autoinsurance.org has released a new blog post presenting a ... insurance policy . , Some types of vehicles cannot be ... newly released blog post to see if their vehicle qualifies for ... are some of the cars that cannot be covered by a ...
(Date:12/26/2014)... 2014 The US represents the largest market ... 2013, GlobalData’s forecast estimates that sales of branded therapies were ... to the high incidence of the disease, high drug treatment ... and China. Increased sales of CRC therapies over the forecast ...
Breaking Medicine News(10 mins):Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 2Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 3Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 4
... , BEDFORD, Mass., July 13 Hologic, Inc. (Hologic ... leading developer, manufacturer and supplier of premium diagnostics, medical ... healthcare needs of women, today announced plans to release ... August 3, 2009 after market close. In conjunction with ...
... July 13 Long term care costs in Wyoming continue ... pressure on those in or near retirement. As a leader ... suite of insurance products to help people proactively plan for ... take advantage of a new program designed to simplify the ...
... WALTHAM, Mass., July 13 Decision Resources, one of the ... healthcare issues, finds that the rheumatoid arthritis (RA) drug market ... in 2008 to $385 million in 2013. This growth will ... to healthcare insurance, greater patient spending power and increased use ...
... , , , ... July 13 CareGuide, Inc., an emerging health management company, welcomes ... as Area Vice President of Sales. Both are located in Texas ... location. , , Julie Sizemore ( ...
... RATON, Fla., July 13 Laura E. Skellchock, M.D. at Integrative ... collagen filler for the correction of smile lines, to treat patients ... has been an avid Artefill user the past several years due ... , , "It,s the perfect ...
... Calif., July 13 Sit ,n Sleep, the mattress ... millions of Southern Californians, today launched a new campaign ... right mattress and improved sleep health and well-being. Widely-known ... in town, Sit ,n Sleep,s new strategic direction ...
Cached Medicine News:Health News:Hologic to Release Third Quarter Fiscal 2009 Operating Results on Monday, August 3, 2009 2Health News:Genworth Financial Simplifies the Process of Purchasing Affordable Long Term Care Insurance for Wyoming AARP Members 2Health News:Genworth Financial Simplifies the Process of Purchasing Affordable Long Term Care Insurance for Wyoming AARP Members 3Health News:Genworth Financial Simplifies the Process of Purchasing Affordable Long Term Care Insurance for Wyoming AARP Members 4Health News:Genworth Financial Simplifies the Process of Purchasing Affordable Long Term Care Insurance for Wyoming AARP Members 5Health News:China's Rheumatoid Arthritis Drug Market Will More than Double by 2013 2Health News:China's Rheumatoid Arthritis Drug Market Will More than Double by 2013 3Health News:CareGuide Adds New Management Team Members 2Health News:Integrative Dermatology of Boca Raton Selects Artefill to Meet Growing Patient Demand for a Longer Lasting Dermal Filler 2Health News:Integrative Dermatology of Boca Raton Selects Artefill to Meet Growing Patient Demand for a Longer Lasting Dermal Filler 3Health News:Sit 'n Sleep Refocuses on Consumer Sleep Health and Well-Being 2Health News:Sit 'n Sleep Refocuses on Consumer Sleep Health and Well-Being 3Health News:Sit 'n Sleep Refocuses on Consumer Sleep Health and Well-Being 4
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: